Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2817-2826

  Surriga, Oliver ^a   Rajasekhar, Vinagolu K ^a   Ambrosini, Grazia ^a   Dogan, Yildrim ^b   Huang, Ruimin ^c   Schwartz, Gary K ^a  

^a Jennifer Goodman Linn Laboratory of New Drug Development   (United States)

^b Cell Biology   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; LUCIFERASE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MELANOMA; MICE; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RNA, SMALL INTERFERING; TUMOR BURDEN; UVEAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890501051     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0499     Document Type: Article

References (38)

1. Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina 2012;32:1363-72
2. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118:1881-5
3. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98:383-9
4. Buzzacco DM, Abdel-Rahman MH, Park S, Davidorf F, Olencki T, Cebulla CM. Long-term survivors with metastatic uveal melanoma. Open Ophthalmology J 2012;6:49-53
5. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J 2012;18:148-52
6. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14:951-6
7. Fournier GA, Albert DM, Arrigg CA, Cohen AM, Lamping KA, Seddon JM. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol 1984;102:80-83
8. Abdel-Rahman MH, Cebulla CM, Verma V, Christopher BN, Carson WE III, Olencki T, et al. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res 2012;100:26-31
9. Harbour JW. The genetics of uveal melanoma: An emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012;25:171-81
10. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3
11. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. Curr Eye Res 2007;32:281-90
12. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011
13. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26
14. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19: 5582-9
15. Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative HGF isoforms through c-Met: Activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene 1999;18:3399-406
16. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGFindependent potentiation of EGFR action by c-Met. Oncogene 2011; 30:3625-35
17. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87
18. Di Cesare S, Marshall JC, Logan P, Antecka E, Faingold D, Maloney SC, et al. Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF. J Carcinogenesis 2007;6:2
19. Abdel-Rahman MH, Boru G, Massengill J, Salem MM, Davidorf FH. MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci 2010;51:3333-9
20. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22
21. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative, and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17
22. Yamazaki S, Skaptason J,Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available c-Met kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008;36:1267-74
23. Daniels KJ, Boldt HC, Martin JA, Gardner LM, Meyer M, Folberg R. Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab Invest 1996;75:55-66
24. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005;92:2032-38
25. De Waard-Siebinga I, Blom DJR, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, et al. Establishment and characterization of an uvealmelanoma cell line. Int J Cancer 1995;62:155-61
26. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis 1997;15: 509-18
27. Luyten GPM, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, Van Drunen E, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer 1996;66:380-7
28. Dogan Y, Ganser A, Scherr M, Eder M. Quantification of transforming capacity and cooperation of defined genetic alterations in myeloid malignancies. Exp Hematol 2010;38:11-9
29. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44: 4651-9
30. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011;17:4425-38
31. Wu X, Zhou J, Rogers AM, Janne PA, Benedettini E, Loda M, et al. c- Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 2012;22:123-32
32. Hendrix MJ, Seftor EA, Seftor RE, Kirschmann DA, Gardner LM, Boldt HC, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol 1998;152:855-63
33. Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, et al. Involvement of PI3K/ Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 2008;49: 497-504
34. Yang H, Fang G, Huang X, Yu J, Hsieh CL, Grossniklaus HE. In vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res 2008;18:95-103
35. Notting IC, Buijs JT, Que I, Mintardjo RE, van der Horst G, Karperien M, et al. Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis. Invest Ophthalmol Vis Sci 2005;46:1581-7
36. Yang H, Jager M, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 2010;51:2835-942
37. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007;21:752-9
38. Logan PT, Fernandes BF, Di Cesare S, Marshall JC, Maloney SC, Burnier MN Jr. Single-cell tumor dormancy model of uveal melanoma. Clin Exp Metastasis 2008;25:509-16